Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · March 01, 2023

Intravitreous Aflibercept for the Prevention of Vision-Threatening Complications of Diabetic Retinopathy

JAMA: The Journal of the American Medical Association

 

Additional Info

JAMA: The Journal of the American Medical Association
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy
JAMA 2023 Feb 07;329(5)376-385, RK Maturi, AR Glassman, K Josic, CW Baker, AT Gerstenblith, LM Jampol, A Meleth, DF Martin, M Melia, OS Punjabi, S Rofagha, H Salehi-Had, CR Stockdale, JK Sun

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading